Floatz logo

Peg-Rhg-Csf

Malignant Solid Tumors

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Phase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

30 Active assets in the Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Zofran
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
DEXAMETHASONE
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Medroxyprogesterone acetate
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Adebelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2CCC

View all 38 →

Same molecule, other indications

Peg-Rhg-Csf is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
BB
Indicative ·
68 / 100
View asset →
Adjuvant ChemotherapyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →